The Commercial Court of Paris ruled against Onxeo SA in its dispute with SpePharm and their 50-50 joint venture SpeBio BV.
SpeBio BV was formed to distribute Loramyc for the treatment of oropharyngeal candidiasis, a yeast/fungal infection.
The court directed Onxeo to pay SpePharm and SpeBio €50,000 and €8.6 million in damages, respectively. SpePharm and SpeBio will also receive procedural indemnities of €15,000 and €250,000, respectively.
Onxeo said it will contest the decision.
The dispute, which Onxeo started in 2009, involves alleged contract breaches by SpePharm and SpeBio that resulted in a delay in the marketing and sales of Loramyc.
Onxeo was formerly known as BioAlliance Pharma.